Last reviewed · How we verify
TAK-360
At a glance
| Generic name | TAK-360 |
|---|---|
| Sponsor | Takeda |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of TAK-360 in Adults With Idiopathic Hypersomnia (PHASE2)
- A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TAK-360 CI brief — competitive landscape report
- TAK-360 updates RSS · CI watch RSS
- Takeda portfolio CI